The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%

Market Analysis and Insights: Global Drugs for Vulvovaginal Candidiasis Market
In 2020, the global Drugs for Vulvovaginal Candidiasis market size was US$ 804.5 million and it is expected to reach US$ 892.9 million by the end of 2027, with a CAGR of 1.5% during 2021-2027.
Global Drugs for Vulvovaginal Candidiasis Scope and Market Size
Drugs for Vulvovaginal Candidiasis market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Drugs for Vulvovaginal Candidiasis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2016-2027.

Segment by Type, the Drugs for Vulvovaginal Candidiasis market is segmented into
Cream
Pessary
Other

Segment by Application, the Drugs for Vulvovaginal Candidiasis market is segmented into
Hospital & Clinic
Pharmacy

Regional and Country-level Analysis:
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Competitive Landscape and Drugs for Vulvovaginal Candidiasis Market Share Analysis
Drugs for Vulvovaginal Candidiasis market competitive landscape provides details and data information by companies. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on sale and revenue by players for the period 2016-2021. Details included are company description, major business, Drugs for Vulvovaginal Candidiasis product introduction, recent developments, Drugs for Vulvovaginal Candidiasis sales by region, type, application and by sales channel.

The major companies include:
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group